Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-56

l couldn't agree with you more; all the signs are there for PTX100 to shine. I look forward to the updates from Prof Miles Prince in regard to the Phase 2 patients, with a cohort of slightly healthier patients at the beginning of their treatments l feel comfortable that our PTX100 program will be well received by firstly the patients and also by the FDA. PTX100 has a very good safety record and has the potential to be friendly with other medications during treatment. I think over the next 12 weeks or so we will see a reasonable elevation in the share price.